ZL016

ZL016 is a glycopeptide immunomodulator developed by Zylacta Corporation for the treatment of chronic liver diseases, including Hepatitis C virus (HCV) infection, hepatic fibrosis, cirrhosis, and non-alcoholic steatohepatitis (NASH). The compound is a glucosaminyl muramyl peptide derived from the enzymatic hydrolysis of peptidoglycan from lactic acid bacteria. Unlike direct-acting antivirals, ZL016 functions by mobilizing the host's immune system and modulating key inflammatory and apoptotic pathways, specifically targeting tumor necrosis factor-alpha (TNF-alpha), FAS antigen, and nuclear factor-kappa B (NF-κB). Clinical data suggests that oral administration of ZL016 reduces markers of liver damage and oxidative stress, such as gamma-glutamyl transpeptidase (GGT), alanine aminotransferase (ALT), and aspartate aminotransferase (AST), while also decreasing viral titers in HCV patients.

Other names

glucosaminyl muramyl peptide